Evidence map›Paper›PMID 36835224›Full record

ArticleInternational journal of molecular sciences2023

Renin-Angiotensin-Aldosterone System Inhibitors and Development of Gynecologic Cancers: A 23 Million Individual Population-Based Study.

Nhi Thi Hong Nguyen, Phung-Anh Nguyen, Chih-Wei Huang, Ching-Huan Wang, Ming-Chin Lin, Min-Huei Hsu, Hoang Bui Bao, Shuo-Chen Chien, Hsuan-Chia Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Angiotensin-converting enzyme inhibitors for ovarian cancer? - a new adjuvant option or a silent trap.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Nhi Thi Hong NguyenSchool of Health Care Administration, College of Management, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0001-7195-6171
Phung-Anh NguyenClinical Data Center, Office of Data Science, Taipei Medical University, Taipei 106339, Taiwan.ORCID 0000-0002-7436-9041
Chih-Wei HuangInternational Center for Health Information Technology (ICHIT), College of Medical Science and Technology, Taipei Medical University, Taipei 106339, Taiwan.ORCID 0000-0002-2551-6199
Ching-Huan WangGraduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 106339, Taiwan.
Ming-Chin LinGraduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 106339, Taiwan.ORCID 0000-0001-9624-9705
Min-Huei HsuClinical Data Center, Office of Data Science, Taipei Medical University, Taipei 106339, Taiwan.
Hoang Bui BaoHealth Personnel Training Institute, University of Medicine and Pharmacy, Hue University, Hue 491-20, Vietnam.
Shuo-Chen ChienInternational Center for Health Information Technology (ICHIT), College of Medical Science and Technology, Taipei Medical University, Taipei 106339, Taiwan.
Hsuan-Chia YangClinical Big Data Research Center, Taipei Medical University Hospital, Taipei 11031, Taiwan.ORCID 0000-0001-9198-0697
Taipei Medical University · TWHue University · VNTaipei Medical University Hospital · TWJohns Hopkins University · USTaipei Medical University-Shuang Ho Hospital · TW

Funding

National Science and Technology Council NSTC 110-2320-B-038 -029 -MY3National Science and Technology Council NSTC 111-2321-B-038-004
6 · The paper itself

Abstract

The chronic receipt of renin-angiotensin-aldosterone system (RAAS) inhibitors including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been assumed to be associated with a significant decrease in overall gynecologic cancer risks. This study aimed to investigate the associations of long-term RAAS inhibitors use with gynecologic cancer risks. A large population-based case-control study was conducted from claim databases of Taiwan's Health and Welfare Data Science Center (2000-2016) and linked with Taiwan Cancer Registry (1979-2016). Each eligible case was matched with four controls using propensity matching score method for age, sex, month, and year of diagnosis. We applied conditional logistic regression with 95% confidence intervals to identify the associations of RAAS inhibitors use with gynecologic cancer risks. The statistical significance threshold was

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsEndometrial NeoplasmsHypertensionOvarian NeoplasmsRenin-Angiotensin SystemCase-Control StudiesFemaleHumansRisk FactorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsACEIsARBscervical cancerendometrial cancergynecologic cancer riskovarian cancerrenin-angiotensin-aldosterone system

Identifiers

PMID36835224
PMCPMC9968233
OpenAlexW4320920632

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.